Abstract
The myelodysplastic syndrome (MDS) occurs in a heterogenous group of patients with varying degrees of cytopenia and an associated morphologic change in their peripheral blood and bone marrow cells which indicate an abnormality in cellular maturation. This condition is also considered to be a preleukemic state because of the tendency to progress into acute myelogenous leukemia in approximately 40% of the patients. A significant number of these patients succumb to the complications of bone marrow failure such as infection and hemorrhage from the resulting cytopenia. Currently, there is no satisfactory specific therapy available for MDS.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Breitman TR, Collins SJ, Keene BR. Terminal differentiation of human promyelocytic cells in primary culture in response to retinoic acid. Blood 57:1000–1004, 1981.
Douer D, Koeffler P. Inhibition of the clonal growth of human myeloid leukemia cells. J Clin Invest 69: 277–283, 1982.
Douer D, Koeffler HP. Retinoic acid enhances growth of human early erythroid progenitor cells in vitro. J Clin Invest 69: 1039, 1982.
Douer D, Koeffler HP. Retinoic acid enhances colony-stimulating factor induced clinical growth of normal human myeloid progenitor cells in vitro. Exp Cell Res 138: 193–198, 1982.
Gold EJ, Mertelsmann RH, Itri LM, Gee T, Arlin Z, Kempin S, Clarkson B, Moore MAS. Phase-1 clinical trial of 13 cis retinoic acid in myelo- dysplastic syndrome. Cancer Treatment Reports 67: 981–986, 1983.
Bennett JM, Catovski D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Salton C. The French-American-British (FAB) Cooperative Group: Proposals for the classification of the myelodysplastic syndromes. Brit J Haematol 51: 189–199, 1982.
Worton RG, McCullough EA, Till JE. Physical separation of hematopoietic stem cells forming colonies in culture. J Cell Physiol 74: 171–182, 1969.
Abrahm JL, Smiley R. Modification of normal human myelopoiesis by 12-0-tetradecanoy1- phorbol-13-acetate (TPA). Blood 58: 1119–1126, 1981.
Iscove NN, Sieber F, Winterhalter KH. Erythroid colony formation in cultures of mouse and human bone marrow. Analysis of the requirement for erythropoietin by gel filtration and affinity chromatography on Agarose-Conconavalin A. J Cell Physiol 83: 309–320, 1973.
Aye MT, Niho Y, Till JE, McCulloch EA. Studies of leukemic cell populations in culture. Blood 44: 205–219, 1974.
Claman HN. Corticosteroids and lymphoid cells. New Eng J Med 287: 388–397, 1972.
Duggan DE, Yeh KC, Matalia N, Ditzier CA, McMahon FG. Bioavailability of oral dexa- methasone. Clin Pharm and Therapeutics 18: 205–209, 1975.
Brophy TR O’R, McCafferty J, Tyrer JH, Eadie MJ. Bioavailability of oral dexamethasone during high dose steroid therapy in neurological patients. Eur J Clin Pharmacol 24: 103–108, 1983.
Kerr IG, Lippman ME, Jenkins J, Myers CE. Pharmacology of 13 cis retinoic acid in humans. Cancer Research 42:2069–2073, 1982.
Seabright M. A rapid banding technique for human chromosomes. Lancet 2: 971–972, 1971.
Dube ID, Eaves CJ, Kalousek DK, Eaves AC. A method for obtaining high quality chromosome preparations from single hemopoietic colonies on a routine basis. Cancer Genetics and Cytogenetics 4: 157–168, 1981.
Besa EC, Granick JL, Itri L, Nowell PC. Complete hematologic and cytogenetic remission in a patient with dysmye1opoietic syndrome treated with 13 cis retinoic acid. Blood 62: 199a, 1983.
Bagby GC. Mechanisms of glucocortico-steroid activity in patients with the preleukemic syndrome (Hemopoietic dysplasia). Leuk Res 4: 571–580, 1980.
Bagby GC. Glucocorticoid therapy in the preleukemic syndrome (Hemopoietic dysplasia). Ann Intern Med 92: 55–58, 1980.
Koeppler H, Robinson WA. 13 cis retinoic acid enhances granulocyte-monocyte colony formation in vitro by normal human bone marrow. Blood 58 (suppl. 1): 112a, 1981.
Asmar S, Beranek M, Herzig, G. Retinoic acid stimulates growth and affects differentiation of normal human myeloid precursors. Clin Res 31: 308A, 1 983.
Bailey-Wood R, May S, Jacobs A. The effect of retinoids on CFU-GM from normal subjects and patients with mye1odysp1 astic syndrome. Br J Hematol 59: 15–20, 1985.
Abrahm JL, Colucci A. 13 cis retinoic acid and dimethylsulfoxide inhibit monocyte differentiation of normal human colony forming units-culture. Blood 58 (Suppl. 1): 104a, 1981.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 The Humana Press Inc.
About this chapter
Cite this chapter
Besa, E.C., Hyzinski, M., Nowell, P., Abrahm, J. (1986). Clinical Trials and in Vitro Studies of 13 CIS Retinoic Acid in the Myelodysplastic Syndrome. In: Meyskens, F.L., Prasad, K.N. (eds) Vitamins and Cancer. Experimental Biology and Medicine, Vol. 10, vol 10. Humana Press. https://doi.org/10.1007/978-1-4612-5006-7_29
Download citation
DOI: https://doi.org/10.1007/978-1-4612-5006-7_29
Publisher Name: Humana Press
Print ISBN: 978-1-4612-9395-8
Online ISBN: 978-1-4612-5006-7
eBook Packages: Springer Book Archive